Group 1 - The core viewpoint of the article highlights the performance of the CSI Hong Kong Stock Connect Innovative Drug Index, which rose by 0.8% to 743.38 points, with a trading volume of 12.742 billion yuan [1] - The index has experienced a decline of 1.19% over the past month, but has increased by 28.61% over the last three months and by 26.81% year-to-date [1] - The index comprises 50 listed companies involved in innovative drug research and development, reflecting the overall performance of innovative drug companies within the Hong Kong Stock Connect framework [1] Group 2 - The top ten weighted companies in the index include Innovent Biologics (11.68%), WuXi Biologics (10.35%), BeiGene (10.3%), CanSino Biologics (9.55%), CSPC Pharmaceutical Group (7.56%), China Biologic Products (6.68%), Hansoh Pharmaceutical (4.26%), Zai Lab (4.07%), 3SBio (3.58%), and WuXi AppTec (3.58%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a sector breakdown showing that biopharmaceuticals account for 48.63%, chemical drugs for 29.62%, pharmaceutical and biotechnology services for 20.56%, and medical commerce and services for 1.19% [2] - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December each year, ensuring that the weight factors are updated accordingly [2]
中证港股通创新药指数上涨0.8%，前十大权重包含再鼎医药等